[Infections and lymphoma during prolonged immunosuppression in vascular diseases].
Service de médecine interne, hôpital Cochin, Paris, France. loic.guillevin@wanadoo.fr
L
L
Guillevin
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D053590:Interleukin 1 Receptor Antagonist Protein; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008223:Lymphoma / Q000276:immunology*; D008727:Methotrexate / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy; D009894:Opportunistic Infections / Q000276:immunology* / Q000517:prevention & control; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D012795:Sialoglycoproteins / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D003520:Cyclophosphamide; D008727:Methotrexate